Research Pulse — 2026-09-08 | Brown Biotech

# Research Pulse — 2026-09-08
_Generated 2026-09-08 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 9월 8일 (화요일) · Operationalizing(가동화 Day)**

9/8(가동화) → 9/7(가속) → 9/6(구현) → 9/5(다양화) → 9/4(전이) → 9/3(집적) → 9/2(성숙) → ... → 7/14(가속). Accelerating(9/7)된 기술들이 **실제 운영 환경에서의 구현(Operationalizing) 단계로 이전하며 구체적 임상·산업 성과를 동시에 확보하는 날** — PE-LNP로 체내 간에서 49% prime editing 효율 달성, PAH R408W 페닐케톤뇨제鼠标モデル에서 예상치적 치료 수준 확인(Jiang Nature Nanotechnology 2026), Kresladi(marnetegra-gene autotemcel) LAD-I gene therapy FDA 승인(2026년 3월 26일), 9명 환자 50.9개월 추적 관찰에서 100% alloHSCT-free survival 확인(Sheikh Annals Medicine Surgery 2026 + Booth Journal Human Immunity 2026), inhaled Rentosertib(AI-designed TNIK inhibitor) 흡입형 제형 동물 실험确认, 폐조직 50-70배 집중 +ERK1/2 인산화 저하(Satler AJRCCM 2026), SPLIT(Xenium 신호 정제법)으로 T-cell exhaustion signatures 발견, Bilous et al. Nature Methods 2026, CAR-NKT vs CAR-T spatiotemporal transcriptomic profiling으로 CAR-NKT superior homing/infiltration/fersistence 확인, TIGIT/CD96 blockade 차별적 시너지 확인(Li Signal Transduction 2026), Cervilla et al. 6개 암종 5개 ST 플랫폼 직접 비교 benchmark 완료(Genome Biology 2026)가 동시에 진행된다.

Operationalizing은 Accelerating의 다음 단계다. 오늘 6개 전선은 검증된 기술들이 **실제 운영 환경에서의 구현 단계로 이전하며 구체적 임상·산업 성과를 동시에 확보하는 날**이다.

*출처: [Jiang PE-LNP Prime Editing Nature Nanotechnology 2026](https://consensus.app/papers/details/020416d0f3fa55179bf8ad67a122a32d/), [Sheikh LAD-I Gene Therapy FDA Approval Annals Medicine Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Fung Kresladi First Approval Molecular Diagnosis Therapy 2026](https://consensus.app/papers/details/2011f15a43405ebf91c5196c52777551/), [Booth LAD-I Sustained Efficacy Journal Human Immunity 2026](https://consensus.app/papers/details/6ae712d5d8735cca8240f903ddf6c7f3/), [Satler Inhaled Rentosertib AJRCCM 2026](https://consensus.app/papers/details/1b69782ae2605d0f8d8b22639574d68e/), [Bilous SPLIT Xenium Signal Nature Methods 2026](https://consensus.app/papers/details/776a2368e88e553cbba6c5e99efd3e21/), [Li CAR-NKT vs CAR-T Spatiotemporal Signal Transduction 2026](https://consensus.app/papers/details/511d52c092d55da6974ad8c03e6d7e9f/), [Cervilla ST Platform Benchmark Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/)*

*#OperationalizingDay #Jiang #NatureNanotechnology #PELNP #PrimeEditing #49Percent #InVivo #Sheikh #Kresladi #LADI #GeneTherapy #FDAApproval #Booth #JournalHumanImmunity #AlloHSCTFree #Satler #Rentosertib #Inhaled #TNIK #AJRCCM #IPF #PulmonaryFibrosis #Bilous #SPLIT #NatureMethods #Xenium #SignalPurification #Li #CAR-NKT #CART #Spatiotemporal #SignalTransduction #Cervilla #GenomeBiology #STPlatform #Benchmark #Operationalizing #Accelerating #ClinicalTranslation #Industrialization #GeneEditing #DeliverySystem #LNP #RareDisease #Pediatric #GeneTherapy #AI #DrugDiscovery #TNIKInhibitor #InhaledFormulation #SpatialTranscriptomics #CellTherapy #SolidTumor #DailyReport*

---

### Post 2: CRISPR & Gene Editing — PE-LNP 49% In Vivo Liver Editing과 LNP Optimization 체계화

🪄 **[CRISPR/Gene Editing] PE-LNP로 체내 간에서 49% prime editing 효율 달성, PAH R408W 페닐케톤뇨제鼠标モデル에서 예상치적 치료 수준 확인(Jiang Nature Nanotechnology 2026) + PE-LNP optimization platform 체계화 + off-target 최소화 + 반복 투여 가능 확인 + 비바이러스성 transient delivery의 산업적 우위 재확인 + PE-eVLPs · virus-mimicking nanosystems · extracellular vesicles 등 non-viral delivery 플랫폼 종합(Lummerstorfer Drug Delivery 2026 + Yang MedComm 2026): CRISPR의 Operationalizing(가동화) 동시 확인**

CRISPR 유전자 편집 기술의**실제 운영 환경 구현(Operationalizing)**이 출처에서 동시에 확인된다[1][2][3].

**PE-LNP: 체내 간에서 49% Prime Editing + PAH 모델 치료 수준 확인[1]**
A. Jiang et al.(Nature Nanotechnology 2026)의 연구는 PE-LNP(prime editing lipid nanoparticle) 최적화 플랫폼을 제시한다. **배경**: 기존 PE-LNP의 낮은 효율 문제 — 복잡한 3성분 prime editing system(PE3 or PE5)의 비바이러스성 체내 전달 어려움. **최적화 워크플로우**: (i) Cas9 nickase + reverse transcriptase fusion protein, (ii) pegRNA, (iii) nicking sgRNA의 3성분 복합체 전달 최적화. **핵심 성과 1 — 49% 평균 체내 간 prime editing**: 단일 투여 2mg/kg으로 mouse liver에서 49% 평균 효율. **핵심 성과 2 — PAH R408W 치료 확인**: 페닐케톤뇨증 마우스 모델에서 치료적 수준 phenylalanine 감소 달성. **핵심 성과 3 — Off-target 최소화**: DNA 전달 대비 off-target editing 현저히 감소. **핵심 성과 4 — 간 효소 일시적 상승만 관찰**: 장기 독성 없음. **핵심 성과 5 — 반복 투여 가능**: efficiency further 향상. ** Transient delivery의 우위**: viral vectors 대비 off-target 위험 감소, oncogenic integration 배제. 핵심: PE-LNP로 체내 간 49% prime editing 달성 + PAH 치료 수준 확인 — CRISPR Operationalizing.

**Non-Viral Delivery 산업화: PE-LNP + Virus-Mimicking Nanosystems 종합[2][3]**
CRISPR 체내 치료의 non-viral delivery 산업화가 본격화되고 있다. **136건 CRISPR trials (2025년 12월)**: 이中 36건이 in vivo non-viral vector 사용[2]. **PE-LNP의 산업적 의의**: transient expression으로 안전성 향상 + manufacturing 단순화 + 반복 투여 가능[1]. **Virus-mimicking nanosystems + cell-derived extracellular vesicles**: programmable targeting + diverse editors/tissues 적용 가능[3]. **핵심 메시지**: PE-LNP로 prime editing의 산업적 구현 가능성 확보 — CRISPR Operationalizing 산업화.

**9월 7일 Accelerating vs 오늘의 차별점**: 9/7이 **Chakraborty Molecular Therapy**으로 **Casgevy 역사적 승인 Epoch**를, **Freedman Nature Reviews Genetics**으로 **체외 monitoring toolkit 체계**를, **Singh Cureus**으로 **hematological disorders translational applications**를 제시했다면, 오늘은 **Jiang Nature Nanotechnology**으로 **PE-LNP 49% in vivo liver editing + PAH 치료 수준 확인**을(구체적 치료 성과 Operationalizing), **Lummerstorfer Drug Delivery**으로 **136 trial + 36 non-viral 전환 산업화**를(산업적 Operationalizing), **Yang MedComm**으로 **virus-mimicking nanosystems emerging**을(새 플랫폼 Operationalizing) 동시에 제시한다. Accelerating(9/7) → CRISPR Operationalizing(9/8).

실무 함의: 유전자 치료 전달팀에서 Jiang et al.의 PE-LNP 최적화 워크플로우를 분석하여 prime editing clinical pipeline 전략을 수립해야 한다.

*출처: [Jiang PE-LNP Prime Editing Nature Nanotechnology 2026](https://consensus.app/papers/details/020416d0f3fa55179bf8ad67a122a32d/), [Lummerstorfer Non-Viral CRISPR Clinical Trials Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/), [Yang Delivery Systems MedComm 2026](https://consensus.app/papers/details/87a151ebbb6759e48db9d0a028ff4597/)*

*#CRISPR #GeneEditing #Jiang #NatureNanotechnology #PELNP #PrimeEditing #49Percent #InVivo #Liver #PAH #Phenylketonuria #R408W #OffTarget #TransientDelivery #Yang #MedComm #IonizableLipid #Nanoparticles #VirusMimicking #ExtracellularVesicles #Lummerstorfer #DrugDelivery #136Trials #NonViral #OperationalizingDay #LipidNanoparticle #HitAndRun #Manufacturing #RepeatedDosing #Safety #Oncogenic #Integration #GenomeEditing #TherapeuticIndex #ClinicalTranslation #Industrialization*

---

### Post 3: AI 신약 — Inhaled Rentosertib (AI-Designed TNIK Inhibitor) 흡입형 제형確認과 Precision Oncology Perspectives

💊 **[AI 신약] Insilico Medicine AI-designed Rentosertib(ISM018_055) 흡입형 제형 동물 실험确认, 폐조직 50-70배 집중 +ERK1/2 인산화 저하 + 용량 의존적 폐기능 향상(Satler AJRCCM 2026) + Phase 2a oral 결과(안전성/내약성 확인 + 폐기능 개선) 확인(Yoo BJC Reports 2026) + AI-designed drug의 Phase 2a efficacy · Phase 1/I inhalation safety 이중성으로 실전 검증 체계화: AI drug discovery의 Operationalizing(가동화) 동시 확인**

AI-Driven Drug Discovery의**실제 운영 환경 구현(Operationalizing)**이 출처에서 동시에 확인된다[4][5][6].

**Inhaled Rentosertib: AI-Designed TNIK Inhibitor 흡입형 제형 동물 실험 확인[4]**
C. Satler et al.(American Journal of Respiratory and Critical Care Medicine 2026)의 연구는 inhaled rentosertib의 전신递给 vs 흡입형递给를 비교한다. **배경**: Rentosertib(INS018_055) — TNIK(Traf2- and Nck-interacting kinase) 억제제, Insilico Medicine AI 설계, IPF 치료제. **Phase 2a oral 결과**: safety/tolerability 확인 + lung function 개선. **흡입형 개발动机**: 폐에 최적 노출 도달 + 전신 노출 최소화. ** bleomycin 폐섬유증 마우스 모델**: 72마리 / 4 용량群. **핵심 성과 1 — 폐-혈장 比 50-70배**: 흡입 직후 폐조직 농도, 혈장 比 50-70배 높음. **핵심 성과 2 — ERK1/2 인산화 저하**: dose-dependent. **핵심 성과 3 — 용량 의존적 폐기능 향상**: FVC(forced vital capacity) 증가, Cdyn(compliance) 향상, RL(airway resistance) 감소. **핵심 성과 4 — 섬유증/염증 조직학적 감소**: 최고/차상위 용량群에서. **핵심 성과 5 — 全용량群에서 BALF 백혈구 감소**: 항염증 효과. **핵심 메시지**: inhaled rentosertib로 폐특이적 치료 가능성 확인 — AI-designed drug의吸入型 구현 Operationalizing.

**AI-Designed Drug Clinical Translation: Phase 2a Efficacy · Phase 1 Safety 이중성 체계화[5]**
Wonbeak Yoo et al.(BJC Reports 2026)의 perspective는 AI-driven drug discovery의 임상 이행을 분석한다. **AI-designed TNIK inhibitor Phase 2a trial 결과**: safety/tolerability + pharmacodynamic target engagement + functional decline 경향 확인. **핵심 메시지**: AI-deriv드 molecules가 임상 시험 진입 가능 확인 — 그러나broader validation · mechanistic understanding · regulatory alignment 필요. **Precision oncology 적용 전망**: multi-omics integration · federated model validation · adaptive trial design 전략 제시. 핵심: AI-designed drug의 Phase 2a 성공 +吸入型 확대 — AI drug discovery Operationalizing.

**AI Drug Discovery 현주소: Phase IIa/I 이중성 재확인[6]**
AI drug discovery의 현재 단계는 double-edged 현실을 보인다. **Phase IIa efficacy**: AI-discovered/originated candidate encouraging efficacy 달성[Seyhan 2026, Mao 2026]. **Phase I safety signals**: 다른 candidate safety signals로 정체[Mao 2026]. **Zero fully AI-approved drug**: 아직 fully AI-discovered drug 0개 승인[Yoo 2026]. **핵심**: AI-designed TNIK inhibitor의吸入型 확대 + Phase 2a oral 성공으로 Operationalizing 가시화 — AI drug discovery Operationalizing.

**9월 7일 Accelerating vs 오늘의 차별점**: 9/7이 **Ali Drug Development Research**으로 **AI drug discovery 全단계 통합**을, **Seyhan Critical Reviews**으로 **Phase IIa/I 이중성**을 제시했다면, 오늘은 **Satler AJRCCM**으로 **inhaled rentosertib 폐-혈장 比 50-70배 + dose-dependent ERK1/2 저하 + 조직학적 섬유증 감소**를(구체적吸入型 구현 Operationalizing), **Yoo BJC Reports**으로 **Phase 2a oral 성공 + precision oncology framework**를(실전 이행 Operationalizing), **Mao Frontiers Pharmacology**으로 **Phase IIa/I double-edged 현실 체계화**를(현실 Operationalizing) 동시에 제시한다. Accelerating(9/7) → AI drug discovery Operationalizing(9/8).

실무 함의: AI drug discovery 협업팀에서 Satler et al.의吸入型 결과를 분석하여 inhaled AI-designed drug development strategy를 수립해야 한다.

*출처: [Satler Inhaled Rentosertib AJRCCM 2026](https://consensus.app/papers/details/1b69782ae2605d0f8d8b22639574d68e/), [Yoo Precision Oncology AI Age BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Mao AI Drug Discovery Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)*

*#AI #DrugDiscovery #Satler #AJRCCM #Rentosertib #Inhaled #TNIK #IPF #PulmonaryFibrosis #LungPlasmaRatio #5070Fold #ERK1 #2 #FVC #Cdyn #AirwayResistance #Bleomycin #Yoo #BJcReports #PrecisionOncology #Phase2a #AdaptiveTrial #FederatedModel #Mao #FrontiersPharmacology #PhaseIIa #PhaseI #DoubleEdged #ZeroAIApproval #InsilicoMedicine #AIDesigned #InhalationFormulation #TargetEngagement #FunctionalDecline #OperationalizingDay #DrugDevelopment #ClinicalTranslation #Respiratory #Fibrosis #LungTargeting #SystemicExposure #DoseDependent #Biomarker #TherapeuticIndex*

---

### Post 4: 단백질 AI — AlphaFold Quality Assessment와 SPLIT Xenium Signal Purification의 산업적 적용

🔬 **[단백질 AI] Sarti et al.의 AlphaFold predictions arity map 기반 품질 평가 체계 + abstraqt per-residue scoring function 확립(Bioinformatics Advances 2026) + Bilous et al. SPLIT method로 Xenium 데이터 신호 정제 후 T-cell exhaustion signatures 발견(Nature Methods 2026) + AlphaFold-like model의 protein-ligand drug discovery 적용 데이터 격차 재확인(Singh Current Opinion 2026): 단백질 AI의 Operationalizing(가동화) 동시 확인**

단백질 AI의**실제 운영 환경 구현(Operationalizing)**이 출처에서 동시에 확인된다[7][8][9].

**AlphaFold Quality Assessment: Arity Map + abstraqt Scoring 체계화[7]**
Edoardo Sarti et al.(Bioinformatics Advances 2026): AlphaFold2 predictions의 품질 평가 체계를 제시한다. **pLDDT 한계**: 30-40% residues가 low-confidence range. **Wasserstein PCA 기반 arity map**: 단백질을 3개群으로 분류 — well-folded proteins, IDPs, physically implausible predictions. **abstraqt scoring function**: hallucinated helices · distorted beta strands 식별. **향상된 품질 예측**: pLDDT 보완. 핵심: AlphaFold predictions의 arity map 기반 품질 평가 체계 확립 — 단백질 AI Operationalizing.

**SPLIT: Xenium Spatial Transcriptomics Signal Purification[8]**
Mariia Bilous et al.(Nature Methods 2026): SPLIT(Spatial Purification of Layered Intracellular Transcripts) 방법을 제시한다. **Xenium 데이터 한계**: transcript spillover로 인한 signal contamination 문제. **40개 이상 breast/lung tumor sections**: 다양한 gene panels로 comprehensive Xenium dataset. **SPLIT 적용 결과**: (i) background correction 향상, (ii) cell-type resolution 개선, (iii) **T-cell exhaustion signatures 발견**: malignant cell colocalization과 연관된 T-cell exhaustion signatures 확인 — 기존 방법론으로는 확인 어려웠던 신호. **핵심**: SPLIT으로 Xenium 신호 정제 후才发现된 T-cell exhaustion biology — spatial transcriptomics Operationalizing.

**AlphaFold-Like Model: Protein-Ligand Drug Discovery 데이터 격차 재확인[9]**
Sukrit Singh et al.(Current Opinion in Structural Biology 2026): AlphaFold-like model의 drug discovery 적용 한계를 재확인한다. **hierarchical framework**: 현재 models가 잘 수행하는 tasks vs challenging/unexplored tasks. **systematic dataset generation 필요성**: frontier models 개발 지원. 핵심: AlphaFold-like model의 SBDD 적용 데이터 격차 — 단백질 AI Operationalizing 한계.

**9월 7일 Accelerating vs 오늘의 차별점**: 9/7이 **Maddipatla Nature Biotechnology**으로 **AlphaFold3 experiment-guided structures**를, **Sarti Bioinformatics Advances**으로 **arity map 품질 평가**를, **Feldman Computational Biotechnology**으로 **adversarial mutation invariance**를 제시했다면, 오늘은 **Sarti Bioinformatics Advances**으로 **abstraqt per-residue scoring으로 pLDDT 보완 체계화**를(품질 평가 Operationalizing), **Bilous Nature Methods**으로 **SPLIT으로 T-cell exhaustion 발견**을(실제才发现된 biology Operationalizing), **Singh Current Opinion**으로 **protein-ligand data gap 재확인**을(한계 Operationalizing) 동시에 제시한다. Accelerating(9/7) → 단백질 AI Operationalizing(9/8).

실무 함의: 전산단백질 설계팀에서 Sarti et al.의 arity map 접근법과 Bilous et al.의 SPLIT 결과를 분석하여 protein structure quality assessment + spatial transcriptomics data analysis strategy를 수립해야 한다.

*출처: [Sarti AlphaFold Quality Assessment Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbcbc1980b532f3/), [Bilous SPLIT Xenium Signal Nature Methods 2026](https://consensus.app/papers/details/776a2368e88e553cbba6c5e99efd3e21/), [Singh AlphaFold-like Models Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)*

*#ProteinAI #AlphaFold #Sarti #BioinformaticsAdvances #ArityMap #QualityAssessment #abstraqt #pLDDT #Hallucination #BetaStrand #Bilous #SPLIT #NatureMethods #Xenium #SpatialTranscriptomics #SignalPurification #TcellExhaustion #MalignantColocalization #BackgroundCorrection #CellTypeResolution #Singh #CurrentOpinion #AlphaFoldLike #ProteinLigand #DataGap #HierarchicalFramework #OperationalizingDay #ProteinStructure #DrugDiscovery #SpatialBiology #Benchmark #SignalContamination #Cancer #ImmuneCheckpoint #TranslationalResearch*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — CAPTAIN Multimodal + SCMBench Performance Gap

🬬 **[Single-Cell Multi-Omics Foundation Model] CAPTAIN이 4M cells + 382 proteins로 transcriptomes+proteomes 통합 multimodal foundation model 실현 확인(Ji Nature Communications 2026) + SCMBench로 FM vs DM performance gap 재확인 + lightweight adaptation으로 bridging(Wang Nature Communications 2026) + PerturbNet DE signatures回复에서 superior performance 확인(Li ArXiv 2026): single-cell foundation model의 Operationalizing(가동화) 동시 확인**

Single-Cell Foundation Model의**실제 운영 환경 구현(Operationalizing)**이 출처에서 동시에 확인된다[10][11][12].

**CAPTAIN: Multimodal Foundation Model — Transcriptomes + Proteomes 통합[10]**
Boya Ji et al.(Nature Communications 2026): CAPTAIN multimodal foundation model을 제시한다. **4M+ cells + 382 surface proteins**: concurrently measured transcriptomes + curated proteins. **Human + mouse 다양한 조직**: cross-modality dependencies modeling. **Generalization**: fine-tuning + zero-shot settings 모두에서 robust performance. **Downstream tasks**: protein imputation, expansion, cell type annotation, batch harmonization. **COVID-19 severity 관련 발견**: immune interaction patterns 관련. 핵심: CAPTAIN으로 transcriptomes + proteomes 통합 multimodal foundation model 실현 — foundation model Operationalizing.

**SCMBench: FM vs DM Performance Gap + Lightweight Adaptation[11]**
Yixuan Wang et al.(Nature Communications 2026): SCMBench로 FM vs DM 성능 격차를 재평가한다. **23 methods 평가**: integration accuracy, biomarker detection, trajectory inference, batch effect correction. **FMs < DMs 확인**: foundation models이 state-of-the-art domain-specific models에 미치지 못함. **Lightweight adaptation으로 bridging**: performance gap 해소 가능. 핵심: SCMBench로 FM vs DM 격차 재확인 + lightweight adaptation bridging — foundation model Operationalizing.

**PerturbNet: DE Signatures Superior Performance[12]**
Lanxiang Li et al.(ArXiv 2026): PerturbNet의 differential expression signatures 회복 성능을 분석한다. **Task 1-2에서 PerturbNet**: differential expression signatures 회복에서 최고 성능. **Task 3 한계**: dataset heterogeneity로 cell types 간 generalization 실패. 핵심: PerturbNet의 Task 1-2 강점 + Task 3 generalization 한계 — foundation model Operationalizing 한계.

**9월 7일 Accelerating vs 오늘의 차별점**: 9/7이 **Ji Nature Communications**으로 **CAPTAIN 4M cells + 382 proteins multimodal 통합**을, **Wang Nature Communications**으로 **SCMBench FM vs DM 격차 재확인**을, **Cen MedComm**으로 **single-cell spatial omics review**를 제시했다면, 오늘은 **Ji Nature Communications**으로 **CAPTAIN의 COVID-19 immune interaction patterns 발견**을(발견 Operationalizing), **Wang Nature Communications**으로 **lightweight adaptation bridging 전략**을(적용 Operationalizing), **Li ArXiv**으로 **PerturbNet Task 1-2 강점 + Task 3 한계**를(한계 Operationalizing) 동시에 제시한다. Accelerating(9/7) → Foundation model Operationalizing(9/8).

실무 함의: 단일세포 연구팀에서 Ji et al.의 CAPTAIN multimodal 접근법과 Wang et al.의 lightweight adaptation 결과를 분석하여 foundation model application strategy를 수립해야 한다.

*출처: [Ji CAPTAIN Multimodal Foundation Model Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Foundation Models Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/)*

*#SingleCell #FoundationModel #CAPTAIN #Ji #NatureCommunications #Multimodal #Proteomics #Transcriptomics #COVID19 #ImmuneInteraction #Wang #SCMBench #FMvsDM #LightweightAdaptation #PerformanceGap #OperationalizingDay #BatchHarmonization #CellTypeAnnotation #ProteinImputation #ZeroShot #FineTuning #CellularState #PerturbNet #Perturbation #DifferentialExpression #Benchmark #Generalization*

---

### Post 6: FDA/규제 — Kresladi LAD-I Gene Therapy FDA 승인(2026-03-26)과 지속적疗效确认

📋 **[FDA/규제] Kresladi(marnetegra-gene autotemcel) LAD-I gene therapy FDA 승인(2026년 3월 26일) 확인(Sheikh Annals Medicine Surgery 2026 + Fung Molecular Diagnosis Therapy 2026) + Booth et al. 9명 환자 50.9개월 추적 관찰에서 100% alloHSCT-free survival + sustained CD18 expression 확인(Journal Human Immunity 2026) + 2025년 10개 protein kinase inhibitor 신규 승인 현황 재확인(Roskoski Pharmacological Research 2026): FDA 규제의 Operationalizing(가동화) 동시 확인**

FDA/규제의**실제 운영 환경 구현(Operationalizing)**이 출처에서 동시에 확인된다[13][14][15].

**Kresladi LAD-I Gene Therapy: FDA 승인(2026-03-26) 확인[13][14]**
M. Sheikh et al.(Annals of Medicine and Surgery 2026): Kresladi(marnetegra-gene autotemcel) FDA 승인을 보고한다. **LAD-I 질환**: ITGB2 유전자 돌연변이로 인한罕见 자가면역결핍, 2세までに75% 사망률. **FDA 승인**: 2026년 3월 26일 — pediatric patients with severe LAD-I without matched sibling donor 대상. ** 치료 원리**: autologous CD34+ hematopoietic stem cell gene therapy — lentiviral vector로 functional ITGB2 addition. **Fung et al.**: Kreslad의 개발 milstones 체계적 정리 — Rocket Pharmaceuticals 개발. 핵심: Kresladi LAD-I gene therapy FDA 승인(2026-03-26) — rare disease gene therapy Operationalizing.

**Kresladi 장기疗效 확인: 9명 50.9개월 추적 100% alloHSCT-Free Survival[14]**
Claire Booth et al.(Journal of Human Immunity 2026): Kresladi(rp-L201) 장기 추적 결과를 보고한다. **대상**: 9명 환자, infusion時 age 9.8-117.4개월. **추적 기간**: 중앙값 50.9개월(42.6-67.9개월). **핵심 성과 1 — 100% alloHSCT-free survival**: graft failure 없음. **핵심 성과 2 — Durable VCN**: 3개월 0.42-2.4 → 12개월 mean 1.73, sustained through M24+. **핵심 성과 3 — Sustained CD18 expression**: PMN CD18 expression 지속적 회복. **핵심 성과 4 — 감염 90.7% 감소**: 중증 감염으로 인한 입원 연간 events 현저히 감소. **핵심 성과 5 — Favorable safety profile**: RP-L201 related adverse events 없음, highly polyclonal integration. 핵심: Kresladi 9명 50.9개월 추적 100% alloHSCT-free survival — gene therapy Operationalizing疗效확인.

**2025년 Protein Kinase Inhibitor 10개 신규 승인 현황 재확인[15]**
Robert Roskoski(Pharmacological Research 2026): 2025년 10개 신규 승인 포함 94개 전체 현황을 보고한다. **10개 신규 승인**: avutometinib(MEK1/2), defactinib(FAK), delgocitinib(JAK), mirdametinib(MEK1/2), remibrutinib(BTK), rilzabrutinib(BTK), sunvozertinib(EGFR), taletrectinib(ROS1), vimseltinib(CSF1R), zongertinib(HER2). **94개 전체**: dual specificity MEK1/2 6개, protein-serine/threonine 14개, nonreceptor tyrosine 26개, receptor tyrosine 48개. 핵심: 2025년 10개 protein kinase inhibitor 신규 승인 — FDA 규제 Operationalizing.

**9월 7일 Accelerating vs 오늘의 차별점**: 9/7이 **Roskoski Pharmacological Research**으로 **2025년 10개 kinase inhibitor 신규 승인**을, **Joseph AJHP**으로 **2026 Q2-Q1 2027 60개 pipeline regroup**을 제시했다면, 오늘은 **Sheikh Annals Medicine Surgery**으로 **Kresladi FDA 승인(2026-03-26)**을(구체적 승인 Operationalizing), **Booth Journal Human Immunity**으로 **9명 50.9개월 100% alloHSCT-free survival**을(구체적疗效 Operationalizing), **Roskoski Pharmacological Research**으로 **10개 신규 승인 상세 목록**을(구체적 현황 Operationalizing) 동시에 제시한다. Accelerating(9/7) → FDA 규제 Operationalizing(9/8).

실무 함의: 규제 기획팀에서 Booth et al.의 Kresladi 장기疗效 결과를 분석하여 rare disease gene therapy regulatory strategy를 수립해야 한다.

*출처: [Sheikh LAD-I Gene Therapy FDA Approval Annals Medicine Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Fung Kresladi First Approval Molecular Diagnosis Therapy 2026](https://consensus.app/papers/details/2011f15a43405ebf91c5196c52777551/), [Booth LAD-I Sustained Efficacy Journal Human Immunity 2026](https://consensus.app/papers/details/6ae712d5d8735cca8240f903ddf6c7f3/), [Roskoski FDA Protein Kinase Inhibitors Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/)*

*#FDA #Regulatory #Sheikh #Kresladi #LADI #GeneTherapy #FDAApproval #March2026 #Fung #MolecularDiagnosisTherapy #RocketPharmaceuticals #Booth #JournalHumanImmunity #AlloHSCTFree #100Percent #CD18 #VCN #50Months #SafetyProfile #Polyclonal #Integration #Roskoski #PharmacologicalResearch #KinaseInhibitor #2025Approval #Avutometinib #Defactinib #Delgocitinib #Mirdametinib #Remibrutinib #Rilzabrutinib #Sunvozertinib #Taletrectinib #Vimseltinib #Zongertinib #OperationalizingDay #RareDisease #Pediatric #GeneTherapy #CD34 #Lentiviral #Autoimmune #Immunodeficiency #Survival #ClinicalTranslation #LongTermFollowUp #Immunology*

---

### Post 7: Spatial Transcriptomics — CAR-NKT Superior Homing vs CAR-T Spatiotemporal Profiling과 ST 플랫폼 Benchmark

🗺️ **[Spatial Transcriptomics] CAR-NKT vs CAR-T spatiotemporal transcriptomic profiling으로 CAR-NKT superior tumor homing/infiltration/persistence 확인, TIGIT vs CD96 blockade 차별적 시너지 확인(Li Signal Transduction 2026) + Cervilla et al. 6개 암종 5개 ST 플랫폼(Xenium · Visium · CosMx 등) 직접 비교 benchmark 완료(Genome Biology 2026) + Wen et al. spatial transcriptomics 종양학 응용 종합 review(Wen Cell Death Discovery 2026): spatial transcriptomics의 Operationalizing(가동화) 동시 확인**

Spatial Transcriptomics의**실제 운영 환경 구현(Operationalizing)**이 출처에서 동시에 확인된다[16][17][18].

**CAR-NKT vs CAR-T: Spatiotemporal Profiling으로 Differential Dynamics 확인[16]**
Yan-Ruide Li et al.(Signal Transduction and Targeted Therapy 2026): CAR-T와 CAR-NKT의 spatiotemporal transcriptomic profiling을 비교한다. **CAR-NKT 우위 1 — Superior tumor homing**: NKT cells의 고유한 조직 homing 능력. **CAR-NKT 우위 2 — Superior infiltration**: CAR-T 대비 tumor 내부 침윤 향상. **CAR-NKT 우위 3 — Prolonged in vivo persistence**: 장기 생존. **CAR-NKT 우위 4 — Unique immune checkpoint receptor landscape**: CD96 blockade에 더 민감. **CAR-T 시너지 — TIGIT blockade**: CAR-T + TIGIT blockade synergistic antitumor response. **CAR-NKT 시너지 — CD96 blockade**: CAR-NKT + CD96 blockade greater sensitivity. **Spatiotemporal profiling**: multiple tissues + longitudinal time points에서 통합적 분석. 핵심: CAR-NKT vs CAR-T spatiotemporal profiling으로 cell therapy 선택 기준 구체화 — spatial/ immunotherapy Operationalizing.

**Spatial Transcriptomics Platform Benchmark: 5개 플랫폼 직접 비교[17]**
Sergi Cervilla et al.(Genome Biology 2026): 5개 상업용 ST 플랫폼을 동일 샘플에서 직접 비교한다. **5개 플랫폼**: Visium v1, Visium v2/CytAssist, Visium HD, Xenium, CosMx. **6개 암종**: matched FFPE human tumor sections. **평가维度**: transcript/UMI detection, gene-histology concordance, cell type recovery, targeted protein panel integration. **핵심 발견 1 — Xenium Prime vs Xenium Multi-Tissue**: 동일 화학/이미징 인프라에도 transcript recovery·spatial signal 차이. **핵심 발견 2 — RNA-protein decoupling**: Visium targeted protein + matched RNA 통합 결과에서 widespread RNA-protein 불일치 발견. **핵심 발견 3 — Resolution vs tissue context trade-off**: spatial resolution과 tissue context 사이 트레이드오프. **Harmonized dataset**: ST community 위한 기술적 reference 제공. 핵심: 5개 ST 플랫폼 직접 benchmark로 각 플랫폼 강점/한계 구체화 — spatial transcriptomics Operationalizing.

**Spatial Transcriptomics 종양학 응용: Comprehensive Review[18]**
Qiang Wen et al.(Cell Death Discovery 2026): spatial transcriptomics의 종양学研究 응용을 종합한다. **종양 이질성**: tumor sub-regions, substructures, heterogeneity and plasticity 파악. **종양 미세환경**: immune cell infiltration, activation, suppression 분석. **악성 종양 변환**: precancerous lesions에서 tumorigenesis, immune escape 이해. **표적 치료 개발**: drug resistance 요인, therapy response 예측. 핵심: spatial transcriptomics 종양학 응용 종합 — methodology Operationalizing.

**9월 7일 Accelerating vs 오늘의 차별점**: 9/7이 **Zhang Cell Reports Medicine**으로 **SCLC 600K cells LNM subclusters**를, **Li Cell Reports Medicine**으로 **pan-cancer 56 LCPs + 13 niches**를, **Gao Nature Communications**으로 **gastric cancer LAR**을 제시했다면, 오늘은 **Li Signal Transduction**으로 **CAR-NKT vs CAR-T spatiotemporal profiling으로 TIGIT/CD96 차별적 시너지**를(새 비교 각도 Operationalizing), **Cervilla Genome Biology**으로 **5개 ST 플랫폼 benchmark로 플랫폼별 강점/한계 구체화**를(표준화 Operationalizing), **Wen Cell Death Discovery**으로 **spatial transcriptomics 종양학 응용 종합**을(방법론 Operationalizing) 동시에 제시한다. Accelerating(9/7) → Spatial transcriptomics Operationalizing(9/8).

실무 함의: spatial transcriptomics 연구팀에서 Li et al.의 CAR-NKT vs CAR-T profiling 결과를 분석하여 cell therapy selection + spatial combination strategy를 수립해야 한다.

*출처: [Li CAR-NKT vs CAR-T Spatiotemporal Signal Transduction 2026](https://consensus.app/papers/details/511d52c092d55da6974ad8c03e6d7e9f/), [Cervilla ST Platform Benchmark Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/), [Wen Spatial Transcriptomics Cancer Cell Death Discovery 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/)*

*#SpatialTranscriptomics #Li #SignalTransduction #CARNKT #CART #Spatiotemporal #SuperiorHoming #Infiltration #Persistence #TIGIT #CD96 #Checkpoint #Blockade #Synergy #Differential #Cervilla #GenomeBiology #STPlatform #Benchmark #Visium #Xenium #CosMx #FFPE #RNAProteinDecoupling #Resolution #TissueContext #Wen #CellDeathDiscovery #Cancer #TumorMicroenvironment #Heterogeneity #Plasticity #ImmuneInfiltration #DrugResistance #PrecisionMedicine #OperationalizingDay #CellTherapy #SolidTumor #SpatialBiology #Immunotherapy #ComparativeAnalysis #PlatformSelection*

---

### Post 8: 오늘의 요약 — Operationalizing(가동화 Day) 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

9/8(Operationalizing)의 핵심: Accelerating(9/7)된 기술들이 **실제 운영 환경에서의 구현(Operationalizing) 단계로 이전하며 구체적 임상·산업 성과를 동시에 확보하는 날**이었다.

**1. PE-LNP 49% In Vivo Liver Editing + PAH R408W 치료 수준 확인(Jiang Nature Nanotechnology 2026)**: 단일 투여 2mg/kg으로 mouse liver 49% prime editing + phenylketonuria 치료적 수준 확인 + off-target 최소화 + 반복 투여 가능 — CRISPR Operationalizing. [Jiang Nature Nanotechnology 2026]

**2. Inhaled Rentosertib 폐-혈장 比 50-70배 + ERK1/2 저하 + 조직학적 섬유증 감소(Satler AJRCCM 2026)**: AI-designed TNIK inhibitor 흡입형 제형으로 폐특이적 노출 향상 + dose-dependent lung function 개선 + inflammation/fibrosis 조직학적 감소 — AI drug discovery Operationalizing. [Satler AJRCCM 2026; Yoo BJC Reports 2026]

**3. SPLIT(Xenium Signal Purification)으로 T-cell Exhaustion Signatures 발견(Bilous Nature Methods 2026)**: SPLIT으로 transcript spillover 정제 후才发现된 T-cell exhaustion signatures + malignant cell colocalization 연관 발견 — 단백질 AI / Spatial transcriptomics Operationalizing. [Bilous Nature Methods 2026]

**4. Kresladi LAD-I Gene Therapy FDA 승인(2026-03-26) + Booth et al. 9명 50.9개월 추적 100% alloHSCT-Free Survival(Journal Human Immunity 2026)**: FDA 승인 + 100% alloHSCT-free survival + sustained CD18 expression + 90.7% 감염 감소 — FDA 규제 Operationalizing. [Sheikh Annals Medicine Surgery 2026; Booth Journal Human Immunity 2026]

**5. CAR-NKT vs CAR-T Spatiotemporal Profiling으로 Superior Homing/Infiltration/Persistence 확인(Li Signal Transduction 2026) + Cervilla et al. 5개 ST 플랫폼 Benchmark 완료(Genome Biology 2026)**: CAR-NKT superior homing/infiltration/persistence + TIGIT/CD96 blockade 차별적 시너지 + 5개 ST 플랫폼 benchmark로 각 플랫폼 강점/한계 구체화 — Spatial transcriptomics / Cell therapy Operationalizing. [Li Signal Transduction 2026; Cervilla Genome Biology 2026]

**6. CAPTAIN Multimodal Foundation Model + SCMBench Performance Gap(Wang Nature Communications 2026)**: 4M cells + 382 proteins multimodal integration + FM vs DM performance gap + lightweight adaptation bridging — Foundation model Operationalizing. [Ji Nature Communications 2026; Wang Nature Communications 2026]

**9월 9일 전망**: Operationalizing된 기술들의 실제 임상 적용 속도와 산업화 단계 진입이 핵심 변수. 특히 PE-LNP의 비임상적 확인에서 임상 단계 진입, Kresladi의 현실 임상 환경 적용, inhaled rentosertib의 Phase 2b/3 진행, CAR-NKT의 임상 시험 진행, SPLIT 방법론의 표준화采纳이 관전.

*출처: [Jiang PE-LNP Nature Nanotechnology 2026](https://consensus.app/papers/details/020416d0f3fa55179bf8ad67a122a32d/), [Lummerstorfer Non-Viral CRISPR Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/), [Yang Delivery Systems MedComm 2026](https://consensus.app/papers/details/87a151ebbb6759e48db9d0a028ff4597/), [Satler Inhaled Rentosertib AJRCCM 2026](https://consensus.app/papers/details/1b69782ae2605d0f8d8b22639574d68e/), [Yoo Precision Oncology BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Mao AI Drug Discovery Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Sarti AlphaFold Quality Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbcbc1980b532f3/), [Bilous SPLIT Nature Methods 2026](https://consensus.app/papers/details/776a2368e88e553cbba6c5e99efd3e21/), [Singh AlphaFold-like Current Opinion 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Ji CAPTAIN Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Sheikh Kresladi LAD-I Annals Medicine Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Fung Kresladi Molecular Diagnosis Therapy 2026](https://consensus.app/papers/details/2011f15a43405ebf91c5196c52777551/), [Booth LAD-I Journal Human Immunity 2026](https://consensus.app/papers/details/6ae712d5d8735cca8240f903ddf6c7f3/), [Roskoski Kinase Inhibitors Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/), [Li CAR-NKT vs CAR-T Signal Transduction 2026](https://consensus.app/papers/details/511d52c092d55da6974ad8c03e6d7e9f/), [Cervilla ST Platform Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/), [Wen Spatial Transcriptomics Cancer Cell Death Discovery 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/)*

*#OperationalizingDay #Summary #Jiang #PELNP #PrimeEditing #49Percent #InVivo #PAH #Satler #Rentosertib #Inhaled #TNIK #LungPlasmaRatio #ERK #Yoo #PrecisionOncology #BJC #Bilous #SPLIT #NatureMethods #Xenium #TCellExhaustion #Sheikh #Kresladi #LADI #FDAApproval #Booth #AlloHSCTFree #100Percent #CD18 #Roskoski #KinaseInhibitor #Li #CARNKT #CART #Spatiotemporal #TIGIT #CD96 #Cervilla #STPlatform #Benchmark #Ji #CAPTAIN #Wang #SCMBench #FoundationModel #Operationalizing #Accelerating #ClinicalTranslation #Industrialization #GeneEditing #LNP #RareDisease #AI #DrugDiscovery #Inhalation #SpatialTranscriptomics #CellTherapy #SolidTumor #PrecisionMedicine #DailyReport*

---

## Sources

[1] [Jiang et al. — Efficient prime editing in vivo and in vitro using lipid nanoparticles. Nature Nanotechnology 2026](https://consensus.app/papers/details/020416d0f3fa55179bf8ad67a122a32d/)

[2] [Lummerstorfer et al. — Non-Viral CRISPR carriers: transient delivery with lasting effects. Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/)

[3] [Yang et al. — Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives. MedComm 2026](https://consensus.app/papers/details/87a151ebbb6759e48db9d0a028ff4597/)

[4] [Satler et al. — Inhaled Rentosertib (ISM018_055), a Selective TNIK Inhibitor, Improves Lung Function and Reduces Fibrosis and Inflammation in Animal Models of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2026](https://consensus.app/papers/details/1b69782ae2605d0f8d8b22639574d68e/)

[5] [Yoo et al. — Precision oncology in the age of AI: lessons from AI-driven drug discovery and clinical translation. BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/)

[6] [Mao et al. — Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)

[7] [Sarti et al. — Fold or flop: quality assessment of AlphaFold predictions on whole proteomes. Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbcbc1980b532f3/)

[8] [Bilous et al. — Resolving sensitivity, specificity and signal contamination in Xenium spatial transcriptomics. Nature Methods 2026](https://consensus.app/papers/details/776a2368e88e553cbba6c5e99efd3e21/)

[9] [Singh et al. — More Protein-Ligand data is needed for AlphaFold-like Models to enable drug discovery. Current Opinion in Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)

[10] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/)

[11] [Wang et al. — SCMBench: benchmarking domain-specific and foundation models for single-cell multi-omics data integration. Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/)

[12] [Li et al. — A Systematic Comparison of Single-Cell Perturbation Response Prediction Models. ArXiv 2026](https://consensus.app/papers/details/c9942dcafc665fd59f98c510a131e7e8/)

[13] [Sheikh et al. — Gene therapy for leukocyte adhesion deficiency type I: FDA approval, clinical evidence, and future perspectives. Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/)

[14] [Booth et al. — Autologous Ex Vivo Lentiviral Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I Provides Sustained Efficacy with a Favorable Safety Profile. Journal of Human Immunity 2026](https://consensus.app/papers/details/6ae712d5d8735cca8240f903ddf6c7f3/)

[15] [Roskoski — Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update. Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/)

[16] [Li et al. — Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors. Signal Transduction and Targeted Therapy 2026](https://consensus.app/papers/details/511d52c092d55da6974ad8c03e6d7e9f/)

[17] [Cervilla et al. — A technical comparison of spatial transcriptomics platforms across six cancer types. Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/)

[18] [Wen et al. — Spatial transcriptomics in cancer research: insights into tumorigenesis, diagnosis and therapeutics. Cell Death Discovery 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/)